Prof Arnold Vulto speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the practicality and attitudes around the clinical use of biosimilar monoclonal antibodies from the perspective on an oncologist.
He explains that patients should not be further burdened with the discussions around biosimilar use.
Prof Vulto also addresses the issue of switching to a biosimilar from an originator product or from another biosimilar.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.